Cargando…

Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial

BACKGROUND: Methylphenidate blocks the re-uptake of dopamine by binding to the dopamine transporter in the presynaptic cell membrane and increases extracellular dopamine levels. Similarities in neuropsychologic effects between nicotine and methylphenidate make it an intriguing potential therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurt, Richard D, Ebbert, Jon O, Croghan, Ivana T, Schroeder, Darrell R, Sood, Amit, Hays, J Taylor
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038986/
https://www.ncbi.nlm.nih.gov/pubmed/21276244
http://dx.doi.org/10.1186/1477-5751-10-1
_version_ 1782198159313731584
author Hurt, Richard D
Ebbert, Jon O
Croghan, Ivana T
Schroeder, Darrell R
Sood, Amit
Hays, J Taylor
author_facet Hurt, Richard D
Ebbert, Jon O
Croghan, Ivana T
Schroeder, Darrell R
Sood, Amit
Hays, J Taylor
author_sort Hurt, Richard D
collection PubMed
description BACKGROUND: Methylphenidate blocks the re-uptake of dopamine by binding to the dopamine transporter in the presynaptic cell membrane and increases extracellular dopamine levels. Similarities in neuropsychologic effects between nicotine and methylphenidate make it an intriguing potential therapeutic option. Previous research of methylphenidate in smokers has suggested a possible beneficial effect for the relief of nicotine withdrawal symptoms, but showed no efficacy in helping smokers with attention deficit hyperactivity disorder (ADHD) to stop smoking. METHODS: To investigate potential efficacy for relieving nicotine withdrawal symptoms and promoting smoking abstinence, we conducted a randomized, double-blind, placebo-controlled, phase II study of once-a-day osmotic-release oral system methylphenidate (OROS-MPH, Concerta(®)) at a target dose of 54-mg/day for 8 weeks compared with placebo in 80 adult cigarette smokers. RESULTS: Of the 80 randomized subjects and median smoking rate was 20 cigarettes per day. At the end of the medication phase, the biochemically confirmed 7-day point prevalence smoking abstinence was 10% (4/40) for the placebo group and 2.5% (1/40) for the OROS-MPH group. Nicotine withdrawal was not found to differ significantly between treatment groups during the first 14 days following the start of medication prior to the target quit date (p = 0.464) or during the first 14 days following the target quit date (p = 0.786). CONCLUSION: We observed no evidence of efficacy of OROS-MPH to aid smokers to stop smoking. Although there are biologically plausible hypotheses that support the use of OROS-MPH for treating tobacco dependence, we found no evidence to support such hypotheses. In addition to no increase in smoking abstinence, we saw no effect of OROS-MPH for tobacco withdrawal symptom relief and no change in smoking rates was observed in the OROS-MPH group compared to the placebo group.
format Text
id pubmed-3038986
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30389862011-02-15 Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial Hurt, Richard D Ebbert, Jon O Croghan, Ivana T Schroeder, Darrell R Sood, Amit Hays, J Taylor J Negat Results Biomed Research BACKGROUND: Methylphenidate blocks the re-uptake of dopamine by binding to the dopamine transporter in the presynaptic cell membrane and increases extracellular dopamine levels. Similarities in neuropsychologic effects between nicotine and methylphenidate make it an intriguing potential therapeutic option. Previous research of methylphenidate in smokers has suggested a possible beneficial effect for the relief of nicotine withdrawal symptoms, but showed no efficacy in helping smokers with attention deficit hyperactivity disorder (ADHD) to stop smoking. METHODS: To investigate potential efficacy for relieving nicotine withdrawal symptoms and promoting smoking abstinence, we conducted a randomized, double-blind, placebo-controlled, phase II study of once-a-day osmotic-release oral system methylphenidate (OROS-MPH, Concerta(®)) at a target dose of 54-mg/day for 8 weeks compared with placebo in 80 adult cigarette smokers. RESULTS: Of the 80 randomized subjects and median smoking rate was 20 cigarettes per day. At the end of the medication phase, the biochemically confirmed 7-day point prevalence smoking abstinence was 10% (4/40) for the placebo group and 2.5% (1/40) for the OROS-MPH group. Nicotine withdrawal was not found to differ significantly between treatment groups during the first 14 days following the start of medication prior to the target quit date (p = 0.464) or during the first 14 days following the target quit date (p = 0.786). CONCLUSION: We observed no evidence of efficacy of OROS-MPH to aid smokers to stop smoking. Although there are biologically plausible hypotheses that support the use of OROS-MPH for treating tobacco dependence, we found no evidence to support such hypotheses. In addition to no increase in smoking abstinence, we saw no effect of OROS-MPH for tobacco withdrawal symptom relief and no change in smoking rates was observed in the OROS-MPH group compared to the placebo group. BioMed Central 2011-01-28 /pmc/articles/PMC3038986/ /pubmed/21276244 http://dx.doi.org/10.1186/1477-5751-10-1 Text en Copyright ©2011 Hurt et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hurt, Richard D
Ebbert, Jon O
Croghan, Ivana T
Schroeder, Darrell R
Sood, Amit
Hays, J Taylor
Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial
title Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial
title_full Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial
title_fullStr Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial
title_full_unstemmed Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial
title_short Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial
title_sort methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038986/
https://www.ncbi.nlm.nih.gov/pubmed/21276244
http://dx.doi.org/10.1186/1477-5751-10-1
work_keys_str_mv AT hurtrichardd methylphenidatefortreatingtobaccodependenceinnonattentiondeficithyperactivitydisordersmokersapilotrandomizedplacebocontrolledtrial
AT ebbertjono methylphenidatefortreatingtobaccodependenceinnonattentiondeficithyperactivitydisordersmokersapilotrandomizedplacebocontrolledtrial
AT croghanivanat methylphenidatefortreatingtobaccodependenceinnonattentiondeficithyperactivitydisordersmokersapilotrandomizedplacebocontrolledtrial
AT schroederdarrellr methylphenidatefortreatingtobaccodependenceinnonattentiondeficithyperactivitydisordersmokersapilotrandomizedplacebocontrolledtrial
AT soodamit methylphenidatefortreatingtobaccodependenceinnonattentiondeficithyperactivitydisordersmokersapilotrandomizedplacebocontrolledtrial
AT haysjtaylor methylphenidatefortreatingtobaccodependenceinnonattentiondeficithyperactivitydisordersmokersapilotrandomizedplacebocontrolledtrial